The estimated Net Worth of Capital, L.P.Morton Holding... is at least $203 Millón dollars as of 31 July 2009. Capital Holding owns over 3,500,000 units of Immunogen stock worth over $172,607,248 and over the last 15 years Capital sold IMGN stock worth over $30,240,000.
Capital has made over 1 trades of the Immunogen stock since 2009, according to the Form 4 filled with the SEC. Most recently Capital sold 3,500,000 units of IMGN stock worth $30,240,000 on 31 July 2009.
The largest trade Capital's ever made was selling 3,500,000 units of Immunogen stock on 31 July 2009 worth over $30,240,000. On average, Capital trades about 3,500,000 units every 0 days since 2009. As of 31 July 2009 Capital still owns at least 5,525,200 units of Immunogen stock.
You can see the complete history of Capital Holding stock trades at the bottom of the page.
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding... y Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: